Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

7.540 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 688
Open 7.540
Bid (Size) 7.550 (1)
Ask (Size) 8.000 (1)
Prev. Close 7.540
Today's Range 7.540 - 7.540
52wk Range 6.460 - 20.70
Shares Outstanding 36,130,121
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
UroGen Pharma Ltd. (URGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire

Performance

YTD
-29.5%
-29.5%
1 Month
-21.9%
-21.9%
3 Month
-28.6%
-28.6%
6 Month
-32.4%
-32.4%
1 Year
-41.6%
-41.6%

More News

Read More
Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
Earnings Scheduled For May 12, 2025
Via Benzinga
A Look at UroGen Pharma's Upcoming Earnings Report
Via Benzinga
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Via Chartmill
Top stock movements in today's session.
Via Chartmill
The market is filled with gapping stocks in Friday's session.
Via Chartmill
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
From UroGen Pharma Ltd.
Via Business Wire
UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen
Via Business Wire
UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates
Via Benzinga
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
Via Benzinga
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment
From UroGen Pharma Ltd.
Via Business Wire
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
From UroGen Pharma Ltd.
Via Business Wire
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
From UroGen Pharma Ltd.
Via Business Wire
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
From UroGen Pharma Ltd.
Via Business Wire
Earnings Scheduled For March 10, 2025
Via Benzinga
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
From UroGen Pharma Ltd.
Via Business Wire

Frequently Asked Questions

Is UroGen Pharma Ltd. - Ordinary Shares publicly traded?
Yes, UroGen Pharma Ltd. - Ordinary Shares is publicly traded.
What exchange does UroGen Pharma Ltd. - Ordinary Shares trade on?
UroGen Pharma Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for UroGen Pharma Ltd. - Ordinary Shares?
The ticker symbol for UroGen Pharma Ltd. - Ordinary Shares is URGN on the Nasdaq Stock Market
What is the current price of UroGen Pharma Ltd. - Ordinary Shares?
The current price of UroGen Pharma Ltd. - Ordinary Shares is 7.540
When was UroGen Pharma Ltd. - Ordinary Shares last traded?
The last trade of UroGen Pharma Ltd. - Ordinary Shares was at 05/20/25 04:00 PM ET
What is the market capitalization of UroGen Pharma Ltd. - Ordinary Shares?
The market capitalization of UroGen Pharma Ltd. - Ordinary Shares is 272.42M
How many shares of UroGen Pharma Ltd. - Ordinary Shares are outstanding?
UroGen Pharma Ltd. - Ordinary Shares has 272M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.